Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘
Disclosures: Jorge Cortes is a consultant for Novartis, Pfizer, Takeda, Sun Pharma and Rigel. He has received grant/research support from Novartis and Sun Pharma, and is on the advisory board for Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 64th ASH Annual Meeting & Exposition
